These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39142247)

  • 1. Non-viral vectors combined delivery of siRNA and anti-cancer drugs to reverse tumor multidrug resistance.
    Xue R; Pan Y; Xia L; Li J
    Biomed Pharmacother; 2024 Sep; 178():117119. PubMed ID: 39142247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmable Tetrahedral DNA-RNA Nanocages Woven with Stimuli-Responsive siRNA for Enhancing Therapeutic Efficacy of Multidrug-Resistant Tumors.
    Chen C; Yu M; Li Q; Zhou Y; Zhang M; Cai S; Yu J; Huang Z; Liu J; Kuang Y; Tang X; Chen W
    Adv Sci (Weinh); 2024 Aug; 11(32):e2404112. PubMed ID: 38923806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA.
    Wu Z; Li X; Zeng Y; Zhuang X; Shen H; Zhu H; Liu H; Xiao H
    Basic Clin Pharmacol Toxicol; 2011 Mar; 108(3):177-84. PubMed ID: 21073659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.
    Babu A; Munshi A; Ramesh R
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1391-1401. PubMed ID: 28523942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in Research of Nanotherapeutics for Overcoming Multidrug Resistance in Cancer.
    Maimaitijiang A; He D; Li D; Li W; Su Z; Fan Z; Li J
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance.
    Zhang CG; Yang SD; Zhu WJ; You BG; Liu Y; Yuan ZQ; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
    J Biomed Mater Res B Appl Biomater; 2017 Oct; 105(7):2093-2106. PubMed ID: 27405391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
    Pan J; Mendes LP; Yao M; Filipczak N; Garai S; Thakur GA; Sarisozen C; Torchilin VP
    Eur J Pharm Biopharm; 2019 Mar; 136():18-28. PubMed ID: 30633973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
    Gandhi NS; Tekade RK; Chougule MB
    J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in the study of micelle delivery system reversing multidrug resistance].
    Diao YY; Han M; Chen DW; Gao JQ
    Yao Xue Xue Bao; 2009 Jul; 44(7):710-5. PubMed ID: 19806907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
    Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
    J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer.
    Yuan Y; Cai T; Xia X; Zhang R; Chiba P; Cai Y
    Drug Deliv; 2016 Nov; 23(9):3350-3357. PubMed ID: 27098896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-drug delivery system for the treatment of multidrug-resistant breast cancer: Current status and future perspectives.
    Gao L; Meng F; Yang Z; Lafuente-Merchan M; Fernández LM; Cao Y; Kusamori K; Nishikawa M; Itakura S; Chen J; Huang X; Ouyang D; Riester O; Deigner HP; Lai H; Pedraz JL; Ramalingam M; Cai Y
    Biomed Pharmacother; 2024 Oct; 179():117327. PubMed ID: 39216449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro.
    Zhi F; Dong H; Jia X; Guo W; Lu H; Yang Y; Ju H; Zhang X; Hu Y
    PLoS One; 2013; 8(3):e60034. PubMed ID: 23527297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
    Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
    Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
    Misra R; Das M; Sahoo BS; Sahoo SK
    Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
    Wei G; Yang G; Wei B; Wang Y; Zhou S
    Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.